FDA Approves Vivus’ Obesity Drug, Recommends Against Use In High-Risk Heart Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
A Risk Evaluation and Mitigation Strategy for Qsymia includes prescriber education about the risk of birth defects and limits dispensing to specially certified pharmacies
You may also be interested in...
Can Vivus Get Away Without Outcomes Study Of Obesity Drug Qsymia?
Fixed-dose combination of phentermine and topiramate is FDA-approved for chronic, long-term use, but the average duration in the real world is only about 2.1 months, which is reassuring for Qsymia’s cardiovascular safety, according to a new retrospective claims study.
Women’s Intuition: What Approval Of Sprout’s Addyi Means For Sponsors
Filing for a drug with questionable risk-benefit profile was saved by a trial protocol redesign, strict safety labeling for a narrow indication, a REMS, patient mobilization and plenty of postmarketing studies. Trial period echoes FDA’s approach with a similar sector of lifestyle drug: obesity.
To Market Qsymia, Vivus Takes On Additional Debt
Sales of the weight-loss drug haven’t been brisk, but Vivus can fortify its balance sheet with up to $110 million in debt. Analysts say it could raise more soon, provided it gains a regulatory victory.